Show simple item record

dc.contributor.authorAlQurashi, Naif
dc.contributor.authorHashimi, Saeed M
dc.contributor.authorWei, Ming Q
dc.date.accessioned2017-05-03T15:30:11Z
dc.date.available2017-05-03T15:30:11Z
dc.date.issued2013
dc.date.modified2014-01-15T22:18:25Z
dc.identifier.issn1661-6596
dc.identifier.doi10.3390/ijms14023874
dc.identifier.urihttp://hdl.handle.net/10072/55682
dc.description.abstractThe mammalian target of rapamycin (mTOR) is a critical regulator of many fundamental features in response to upstream cellular signals, such as growth factors, energy, stress and nutrients, controlling cell growth, proliferation and metabolism through two complexes, mTORC1 and mTORC2. Dysregulation of mTOR signalling often occurs in a variety of human malignant diseases making it a crucial and validated target in the treatment of cancer. Tumour cells have shown high susceptibility to mTOR inhibitors. Rapamycin and its derivatives (rapalogs) have been tested in clinical trials in several tumour types and found to be effective as anticancer agents in patients with advanced cancers. To block mTOR function, they form a complex with FKBP12 and then bind the FRB domain of mTOR. Furthermore, a new generation of mTOR inhibitors targeting ATP-binding in the catalytic site of mTOR showed potent and more selective inhibition. More recently, microRNAs (miRNA) have emerged as modulators of biological pathways that are essential in cancer initiation, development and progression. Evidence collected to date shows that miRNAs may function as tumour suppressors or oncogenes in several human neoplasms. The mTOR pathway is a promising target by miRNAs for anticancer therapy. Extensive studies have indicated that regulation of the mTOR pathway by miRNAs plays a major role in cancer progression, indicating a novel way to investigate the tumorigenesis and therapy of cancer. Here, we summarize current findings of the role of mTOR inhibitors and miRNAs in carcinogenesis through targeting mTOR signalling pathways and determine their potential as novel anti-cancer therapeutics.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent813158 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherM D P I AG
dc.publisher.placeSwitzerland
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom3874
dc.relation.ispartofpageto3900
dc.relation.ispartofissue2
dc.relation.ispartofjournalInternational Journal of Molecular Science
dc.relation.ispartofvolume14
dc.rights.retentionY
dc.subject.fieldofresearchOther chemical sciences
dc.subject.fieldofresearchGenetics
dc.subject.fieldofresearchOther biological sciences
dc.subject.fieldofresearchMolecular targets
dc.subject.fieldofresearchcode3499
dc.subject.fieldofresearchcode3105
dc.subject.fieldofresearchcode3199
dc.subject.fieldofresearchcode321108
dc.titleChemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medical Science
gro.rights.copyright© 2013 MDPI (http://www.mdpi.com). The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
gro.date.issued2013
gro.hasfulltextFull Text
gro.griffith.authorWei, Ming Q.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record